Skip to main navigation Skip to search Skip to main content

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

  • Edward Keystone
  • , Désireé Van Der Heijde
  • , David Mason
  • , Robert Landewé
  • , Ronald Van Vollenhoven
  • , Bernard Combe
  • , Paul Emery
  • , Vibeke Strand
  • , Philip Mease
  • , Chintu Desai
  • , Karel Pavelka
  • , Lucian Ionescu

Research output: Contribution to journal › Article › peer-review

550 Scopus citations

Fingerprint

Dive into the research topics of 'Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science